ABS Stock Overview
A clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Arctic Bioscience AS Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NOK 2.14 |
| 52 Week High | NOK 16.80 |
| 52 Week Low | NOK 1.65 |
| Beta | 1.14 |
| 11 Month Change | 29.70% |
| 3 Month Change | -84.71% |
| 1 Year Change | -76.74% |
| 33 Year Change | -89.29% |
| 5 Year Change | n/a |
| Change since IPO | -92.22% |
Recent News & Updates
Shareholder Returns
| ABS | NO Biotechs | NO Market | |
|---|---|---|---|
| 7D | -13.7% | 8.9% | 3.1% |
| 1Y | -76.7% | -69.4% | 3.9% |
Return vs Industry: ABS underperformed the Norwegian Biotechs industry which returned -70.5% over the past year.
Return vs Market: ABS underperformed the Norwegian Market which returned 2.5% over the past year.
Price Volatility
| ABS volatility | |
|---|---|
| ABS Average Weekly Movement | 31.4% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in NO Market | 10.6% |
| 10% least volatile stocks in NO Market | 2.7% |
Stable Share Price: ABS's share price has been volatile over the past 3 months compared to the Norwegian market.
Volatility Over Time: ABS's weekly volatility has increased from 18% to 31% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 17 | Christer Valderhaug | www.arctic-bioscience.com |
Arctic Bioscience AS, a clinical-stage biotechnology company, engages in developing and commercializing pharmaceutical and nutraceutical ingredients based on bioactive marine compounds. The company is developing HRO350, a novel oral drug which is in phase IIb for the treatment of mild-to-moderate psoriasis. It also sells nutraceuticals as intermediary and finished goods products under the ROMEGA brand worldwide.
Arctic Bioscience AS Fundamentals Summary
| ABS fundamental statistics | |
|---|---|
| Market cap | NOK 54.29m |
| Earnings (TTM) | -NOK 48.37m |
| Revenue (TTM) | NOK 31.88m |
1.7x
P/S Ratio-1.1x
P/E RatioIs ABS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABS income statement (TTM) | |
|---|---|
| Revenue | NOK 31.88m |
| Cost of Revenue | NOK 22.24m |
| Gross Profit | NOK 9.64m |
| Other Expenses | NOK 58.00m |
| Earnings | -NOK 48.37m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.91 |
| Gross Margin | 30.23% |
| Net Profit Margin | -151.72% |
| Debt/Equity Ratio | 0% |
How did ABS perform over the long term?
See historical performance and comparison